Menu
Menu
Liquid biopsy is emerging as a revolutionary technology, offering swift and precise diagnostics. It has the potential to significantly impact precision oncology by providing a non-invasive approach for cancer detection, monitoring, and treatment selection. However, liquid biopsy still faces challenges, including workflow standardization and broad adoption across the globe.
Join us for this webinar to learn more about the collaborative efforts of SOPHiA GENETICS, Memorial Sloan Kettering Cancer Center, and AstraZeneca in enhancing global access to and adoption of MSK-ACCESS® powered with SOPHiA DDM™, aimed at addressing disparities in cancer care.
Key topics:
SOPHiA GENETICS is proud to participate in the Congreso Latinoamericano de Patología 2025, taking place in Santiago, Chile.
📍 Visit us at Booth S5
Our team will be on-site to showcase how SOPHiA GENETICS is transforming pathology and laboratory medicine with data-driven insights. Explore our latest innovations across Liquid Biopsy, Solid Tumors, Hematologic Malignancies, and more—empowering clinicians and researchers to advance precision medicine in Latin America.
We look forward to connecting with the pathology community in Santiago and sharing how our technology is shaping the future of healthcare.
Hosted by: SOPHiA GENETICS
Presented by: Alexandre Harlé
Professor of of Biopathology, Head of Precision Medicine and Translational Research Service, Institut de Cancérologie de Lorraine (ICL), France
As precision oncology advances, clinicians and researchers require solid tumor profiling tools that go beyond traditional approaches. While most next-generation sequencing (NGS) solutions rely on DNA as input, RNA sequencing provides unique molecular insights that can inform decision making, particularly from detecting gene fusions, exon skipping, and changes in gene expression. However, practical barriers such as limited tissue availability, complex workflows, and time-consuming interpretation can challenge laboratories implementing RNA sequencing.
In this webinar, Alexandre Harlé, professor and hospital practitioner, will provide an in-depth look at expertly designed RNA NGS solutions for advanced variant detection from solid tumors, including lung and sarcoma. Harlé will share his experience of co-developing and implementing in-house, sample-to-report solutions that address the current and future needs of the Cancer Institute of Lorraine in Nancy, France.
Learning objectives:
Discover the robust analytical performance of an innovative RNA technology that detects novel (partner-agnostic) gene fusions — even when fusion partners are unknown — as well as exon skipping events and gene expression changes from small input amounts. Explore how decentralized sample-to-report workflows with fully integrated analysis, interpretation, and reporting features help accelerate turnaround times and improve operational efficiency.
Understand the value of combining targeted RNA and DNA insights to capture a more comprehensive molecular picture to support informed decision-making.
Speaker Bio:
Professor Alexandre Harlé leads the Precision Medicine and Translational Research group at the Institut de Cancérologie de Lorraine (ICL), France. His research focuses on integrating RNA sequencing and liquid biopsy approaches to better understand tumor biology and improve patient care. He has contributed to collaborative efforts developing RNA-based signatures, such as GemPred, for predicting chemotherapy response in pancreatic cancer. His team is also involved in national studies exploring circulating tumor DNA (ctDNA) for minimal residual disease detection and longitudinal monitoring. Combining clinical expertise with advanced molecular techniques, Harlé’s work aims to support the implementation of precision oncology in routine practice.
SOPHiA GENETICS is excited to attend this year’s Association of Molecular Pathology (AMP) Annual Meeting!
Find us at booth #921 to learn about how we are enabling breakthrough innovations in cancer research.
Wednesday, November 12, 10:00 – 10:50 am | Corporate Workshops | 160C Level 1
Elevating CGP with Agile Solutions: The New MSK-IMPACT® Flex powered with SOPHiA DDM™
Speakers:
Wednesday, November 12, 11:00 – 11:50 am | Corporate Workshops | 160C Level 1
Redefining Precision Oncology with MSK-ACCESS® powered with SOPHiA DDM™
Speakers:
Friday, November 14, 9:15am – 10:15am | Poster number: ST044
Robust RNA profiling using the SOPHiA DDM™ RNAtarget Oncology Solution with FFPE tumor samples
Authored by: Izabela Matyszczak, Slawomir Kubik, Jonathan Bieler, Ewan Smith, Jonathan Lopez, Alexandre Harlé, Christian Pozzorini, Zhenyu Xu
Saturday, November 15, 9:15am – 10:15am | Poster number: ST041
MSK-IMPACT Flex powered with SOPHiA DDM™ enables sample-specific comprehensive genomic profiling through selective analysis of DNA and RNA biomarkers
Authored by: Izabela Matyszczak, Christian Pozzorini, Gregoire André, Tommaso Coletta, Amjad Alkodsi, Frederic Michaud, Yvan Wenger, Elia Magrinelli, Anjali Anjali, Zhenyu Xu
We are thrilled to be back at 15th World Clinical Biomarkers & Companion Diagnostics Summit. Join us and meet our BioPharma team to learn how we help BioPharma companies address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.
If you are attending, don’t miss:
Lunch & Learn hosted by SOPHiA GENETICS on Wednesday, September 24th, from 1.10 to 2.10 pm.
Join us for a special lunch session spotlighting the journey of MSK-ACCESS® powered with SOPHiA DDM™ from an in-house solution at Memorial Sloan Kettering Cancer Center (MSK) to a globally scalable, decentralized, best-in-class liquid biopsy platform, through a strategic collaboration with SOPHiA GENETICS.
Talk on Thursday, September 25th, from 11.00 to 11.30 am, in Track A.
“Bridging the Gap: A Hybrid Deployment Model for Scaling Innovation in Oncology”
Jess Lambe, Vice President and Managing Director of BioPharma Business Development, SOPHiA GENETICS
Join us at ESMO Asia 2025! Learn how we advance data-driven medicine, with our cloud-based SOPHiA DDM™ Platform by leveraging our unique AI-powered expertise and comprehensive product offering. Discover how we uncover insights from complex oncology data, driving faster discovery of new stratifying biomarkers, in addition to aiding in the commercialization of precision medicines.
We are excited to announce our presence at the World Companion Diagnostics & Liquid Biopsy Summit APAC. Meet our BioPharma team to learn more about our liquid biopsy portfolio and how it supports BioPharma companies to address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.
If you are around, don’t miss our Plenary talk, to discover how SOPHiA GENETICS is empowering Pharma companies to advance precision medicine with next-generation genomics solutions, enhancing worldwide patient access to innovative therapies
“Innovative Ways to Democratize Precision Medicine Testing”
Nicholas Tan, Managing Director APAC, SOPHiA GENETICS
If you are around, don't miss our Plenary talk, on November 12th from 12.00 to 12.30 pm, to discover how SOPHiA GENETICS is empowering Pharma companies to advance precision medicine with next-generation genomics solutions, enhancing worldwide patient access to innovative therapies.
We are glad to return to BioTechX Europe in Basel. Meet our BioPharma team and learn how we help BioPharma companies address challenges throughout the drug development continuum with diagnostics and data solutions tailored to their needs, bringing more effective drugs to the right patients.
If you are attending, join us on October 6th at 14:50, in the Big Data in Oncology track, for an engaging talk about how SOPHiA GENETICS is building a world where clinicians make faster, more informed decisions, and every patient contributes to a smarter and more equitable future in medicine
“Unlocking the Power of Data: AI-Driven Insights for Precision Medicine”
Guillaume Cettou, Global Head of Data Partnerships, SOPHiA GENETICS
You’ll get to explore howAI and collective intelligence are translating vast amounts of data into actionable insights, enabling clinicians to make more informed decisions and improving outcomes across borders.
We are glad to be at BioTechX USA 2025, where you will have the chance to meet our BioPharma team for two days of exciting networking, innovation, and insights sharing on the potential of AI-driven solutions to transform precision medicine.
If you are around, don’t miss our talk on September 17th from 12.05 to 12.25 PM, in the AI in Drug Development and Discovery track, for an insightful talk about how SOPHiA GENETICS is building a world where clinicians make faster, more informed decisions, and every patient contributes to a smarter and more equitable future in medicine.
“Unlocking the Power of Data: AI-Driven Insights for Precision Medicine”
Kellen Sanger, Head of Strategy and Programs, SOPHiA GENETICS
You’ll get to explore howAI and collective intelligence are translating vast amounts of data into actionable insights, enabling clinicians to make more informed decisions and improving outcomes across borders.
We’re thrilled to be back at International Congress of Pathology and Laboratory Medicine (ICPALM 2025)
Join SOPHiA GENETICS at Booth S26 as we showcase our latest breakthroughs in data-driven medicine. Discover how our advanced solutions are transforming clinical insights across Liquid Biopsy, Solid Tumors, Hematologic Malignancies, and more.
We look forward to connecting with you in person in Malaysia!
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.